Mineralys Therapeutics is listed as a current portfolio company of Andera Partners on Andera Partners' own portfolio page. Andera Partners has owned Mineralys Therapeutics since 2022, per Andera Partners' portfolio page.
Mineralys Therapeutics is a Clinical-stage biopharmaceutical company committed to developing a best-in-class, novel therapy for the treatment of hypertension company. Its owner on record, Andera Partners, is a private equity firm. Andera Partners lists 291 companies in the index, 36 of them in Clinical-stage biopharmaceutical company committed to developing a best-in-class, novel therapy for the treatment of hypertension.
Andera Partners is a private equity asset management firm that invests in companies and their management to support growth and innovation.
Read the Andera Partners profileMineralys Therapeutics is listed as a current portfolio company of Andera Partners on Andera Partners' own portfolio page. Andera Partners has owned Mineralys Therapeutics since 2022, per Andera Partners' portfolio page.
Mineralys Therapeutics is in Clinical-stage biopharmaceutical company committed to developing a best-in-class, novel therapy for the treatment of hypertension. Classified from the owner's portfolio label.
Andera Partners lists 35 other Clinical-stage biopharmaceutical company committed to developing a best-in-class, novel therapy for the treatment of hypertension companies in the index, including Adler Ortho, AgoMab, AM Pharma, Amolyt Pharma and Artios Pharma.
6 of 290 shown
See the full Andera Partners portfolio.
Browse PE-backed companies.
